Ann Intern Med. 2016 Feb 16;164(4):256-67. doi: 10.7326/M15-0970. Epub 2016 Jan 12.
In 2009, the U.S. Preventive Services Task Force recommended biennial mammography screening for women aged 50 to 74 years and selective screening for those aged 40 to 49 years.
To review studies of screening in average-risk women with mammography, magnetic resonance imaging, or ultrasonography that reported on false-positive results, overdiagnosis, anxiety, pain, and radiation exposure.
MEDLINE and Cochrane databases through December 2014.
English-language systematic reviews, randomized trials, and observational studies of screening.
Investigators extracted and confirmed data from studies and dual-rated study quality. Discrepancies were resolved through consensus.
Based on 2 studies of U.S. data, 10-year cumulative rates of false-positive mammography results and biopsies were higher with annual than biennial screening (61% vs. 42% and 7% vs. 5%, respectively) and for women aged 40 to 49 years, those with dense breasts, and those using combination hormone therapy. Twenty-nine studies using different methods reported overdiagnosis rates of 0% to 54%; rates from randomized trials were 11% to 22%. Women with false-positive results reported more anxiety, distress, and breast cancer-specific worry, although results varied across 80 observational studies. Thirty-nine observational studies indicated that some women reported pain during mammography (1% to 77%); of these, 11% to 46% declined future screening. Models estimated 2 to 11 screening-related deaths from radiation-induced cancer per 100,000 women using digital mammography, depending on age and screening interval. Five observational studies of tomosynthesis and mammography indicated increased biopsies but reduced recalls compared with mammography alone.
Studies of overdiagnosis were highly heterogeneous, and estimates varied depending on the analytic approach. Studies of anxiety and pain used different outcome measures. Radiation exposure was based on models.
False-positive results are common and are higher for annual screening, younger women, and women with dense breasts. Although overdiagnosis, anxiety, pain, and radiation exposure may cause harm, their effects on individual women are difficult to estimate and vary widely.
Agency for Healthcare Research and Quality.
2009 年,美国预防服务工作组建议对年龄在 50 至 74 岁的女性进行每两年一次的乳房 X 光筛查,并对年龄在 40 至 49 岁的女性进行选择性筛查。
对使用乳房 X 光、磁共振成像或超声进行筛查的平均风险女性的研究进行综述,这些研究报告了假阳性结果、过度诊断、焦虑、疼痛和辐射暴露。
MEDLINE 和 Cochrane 数据库,截至 2014 年 12 月。
英语系统评价、随机试验和筛查的观察性研究。
调查人员从研究中提取和确认数据,并对研究质量进行双重评估。通过协商解决了分歧。
基于 2 项美国数据研究,与每两年筛查相比,每年筛查的 10 年累积假阳性乳房 X 光检查结果和活检率更高(分别为 61%和 7%对 42%和 5%),对于年龄在 40 至 49 岁、乳房致密和使用联合激素治疗的女性而言。使用不同方法的 29 项研究报告了 0%至 54%的过度诊断率;随机试验的结果为 11%至 22%。有假阳性结果的女性报告了更多的焦虑、痛苦和对乳腺癌的担忧,尽管 80 项观察性研究的结果各不相同。39 项观察性研究表明,一些女性在乳房 X 光检查过程中报告了疼痛(1%至 77%);其中 11%至 46%的女性拒绝了未来的筛查。基于模型,估计每 10 万名女性中,数字乳房 X 光检查导致 2 至 11 例与筛查相关的癌症死亡,这取决于年龄和筛查间隔。五项关于断层合成术和乳房 X 光检查的观察性研究表明,与单独使用乳房 X 光检查相比,活检增加,但召回减少。
过度诊断的研究高度异质,估计值取决于分析方法。焦虑和疼痛研究使用了不同的结果测量方法。辐射暴露是基于模型的。
假阳性结果很常见,并且每年筛查、年轻女性和乳房致密的女性的假阳性结果更高。虽然过度诊断、焦虑、疼痛和辐射暴露可能会造成伤害,但它们对个体女性的影响很难估计,且差异很大。
医疗保健研究与质量局。